NASDAQ:LXEO Lexeo Therapeutics Q2 2026 Earnings Results & Report $2.63 -0.11 (-4.01%) Closing price 04:00 PM EasternExtended Trading$2.63 0.00 (0.00%) As of 04:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Lexeo Therapeutics missed analyst earnings expectations in its Q2 2026 results, released August 12, 2026. The company reported EPS of -$0.30 versus the -$0.2852 consensus estimate. Research:ProfileEarnings HistoryForecast Earnings Announcement Details QuarterQ2 2026Report DateAugust 12, 2026TimeBefore Market OpensConference Call7:00 AM ET Lexeo Therapeutics EPS ResultsActual EPS-$0.30Consensus EPS -$0.2852Beat/MissMissed by -$0.0148One Year Ago EPSN/AEPS Beat Rate5 of last 8 quartersLexeo Therapeutics Revenue ResultsActual RevenueN/AExpected RevenueN/ABeat/MissN/AYoY Revenue GrowthN/AUpcoming EarningsLexeo Therapeutics' Q3 2026 earnings is estimated for Monday, December 14, 2026, based on past reporting schedulesConference Call ResourcesPress Release (8-K)Quarterly Report (10-Q)Earnings HistoryCompany ProfilePowered by Earnings DocumentsPress Release(8-K)Quarterly report(10-Q) Lexeo Therapeutics Q2 2026 Earnings FAQ Did Lexeo Therapeutics beat earnings estimates for Q2 2026? Lexeo Therapeutics (NASDAQ:LXEO) reported earnings of -$0.30 per share for Q2 2026, missing the consensus estimate of -$0.2852. The report was announced on Wednesday, August 12, 2026. When is Lexeo Therapeutics' next earnings date? Lexeo Therapeutics' next earnings date is estimated for Monday, December 14, 2026. MarketBeat tracks confirmed and estimated earnings dates for Lexeo Therapeutics on the company's earnings history page. Lexeo Therapeutics Earnings HeadlinesLexeo Therapeutics to Participate in the Chardan Healthcare ConferenceOctober 8, 2026 | globenewswire.comStifel Nicolaus Sticks to Its Buy Rating for Lexeo Therapeutics, Inc. (LXEO)October 7, 2026 | theglobeandmail.comWhy major institutions are piling into this digital asset nowBlackRock, JPMorgan, Goldman Sachs, and Fidelity are reportedly accumulating a scarce blockchain asset - one that gets burned with every transaction on what analysts are calling America's new financial grid. The Nasdaq has received SEC approval to move stocks onto blockchain rails, and BlackRock CEO Larry Fink dedicated his entire 2026 annual letter to this infrastructure shift. Blockchain analyst Andy Howard is calling this asset 'Digital Oil' - and says institutional buyers are already positioned.October 14 at 1:00 AM | Awesomely (Ad)Lexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson’s Disease and Movement Disorders 2026 (MDS)October 1, 2026 | finance.yahoo.comLexeo Therapeutics Announces Oral Presentation of LX2006 at the International Congress of Parkinson's Disease and Movement Disorders 2026 (MDS)October 1, 2026 | globenewswire.comLeerink Partners Keeps Their Buy Rating on Lexeo Therapeutics, Inc. (LXEO)September 26, 2026 | theglobeandmail.comSee More Lexeo Therapeutics Headlines Get Earnings Announcements in your inboxWant to stay updated on the latest earnings announcements and upcoming reports for companies like Lexeo Therapeutics? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Lexeo Therapeutics and other key companies, straight to your email. Email Address About Lexeo TherapeuticsLexeo Therapeutics (NASDAQ:LXEO) (NASDAQ:LXEO) is a clinical-stage biotechnology company developing genetic medicines for serious diseases with limited treatment options. The company uses adeno-associated virus (AAV) vectors and other gene therapy technologies to deliver genetic material intended to address underlying causes of disease, with a focus on conditions affecting the central nervous system and cardiovascular system. Lexeo’s pipeline includes LX2006, an investigational gene therapy being developed for Friedreich’s ataxia cardiomyopathy, a potentially life-threatening cardiac complication of Friedreich’s ataxia. The company is also advancing LX1001, an investigational therapy designed to address APOE4-associated Alzheimer’s disease, as well as programs targeting genetically defined cardiovascular diseases, including conditions involving PKP2-related arrhythmogenic cardiomyopathy. Lexeo conducts its research and clinical development activities primarily in the United States and works with academic and clinical institutions to advance its programs. The company was founded to develop genetic medicines for diseases driven by specific genetic abnormalities and is headquartered in New York. Its executive leadership is headed by Chief Executive Officer R. Nolan Townsend.View Lexeo Therapeutics ProfileRead more More Earnings Resources from MarketBeat Earnings Tools Today's Earnings Tomorrow's Earnings Next Week's Earnings Upcoming Earnings Calls Earnings Newsletter Earnings Call Transcripts Earnings Beats & Misses Corporate Guidance Earnings Screener Latest Articles Citi Stock Falls Despite Earnings Beat: What Investors Need to KnowDon’t Get NVIDIA’s Reflection AI Interest Wrong: Its Moat Could DeepenIREN Limited's AI Pivot Gains Traction—But Can Its Data Centers Deliver?PBF Energy's Stunning Rally Faces a Critical TestA Chinese Rival Just Spooked Memory Stocks—How Worried Should Micron Investors Be?Albertsons Is Betting on a Turnaround—But Will It Pay Off?PepsiCo's Earnings Beat Masks a Bigger Problem With Its North American Business Upcoming Earnings Interactive Brokers Group (10/15/2026)Marsh & McLennan Companies (10/15/2026)The PNC Financial Services Group (10/15/2026)Charles Schwab (10/15/2026)U.S. Bancorp (10/15/2026)Prologis (10/15/2026)Taiwan Semiconductor Manufacturing (10/15/2026)Truist Financial (10/16/2026)Travelers Companies (10/16/2026)HDFC Bank (10/17/2026) Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
